MindMed and Forian will collaborate on drug R&D via the real-world evidence (RWE) pathway to drug development.
Exploring the companies and themes that make up this emerging and exciting new sector
Cannabis Firm Plans South Africa IPO, Magic Mushroom Expansion
Cilo Cybin Pharmaceutical Ltd. is considering an initial public offering in the next 12 months after becoming the first South African company to win the right to grow, process and package cannabis products.
Portland Activists Push To Decriminalize Psychedelics Cultivation, Gifting And Community Ceremonies
Portland, Oregon activists are mounting a push to have local lawmakers pass a resolution decriminalizing the cultivation, gifting and ceremonial use of a wide range of psychedelics.
Optimi Health Clears Final Base Shelf Prospectus
Optimi Health announces it has filed a Final Shelf Prospectus.
California Bill To Legalize Possession Of Psychedelics Clears Another Hurdle But Faces Key Challenge Next Week
A Senate-passed bill to legalize possession of certain psychedelics in California cleared a procedural hurdle on Monday—but it faces another critical challenge in the Assembly next week that could decide its fate.
Ann Arbor City Council Declares Psychedelics Awareness Month For September
Nearly one year after the Ann Arbor, Michigan City Council voted to decriminalize a wide-range of psychedelics, lawmakers on Monday approved a resolution to officially designate September as Entheogenic Plants and Fungi Awareness Month.
Cybin Files 14th Patent Application Further Strengthening its IP Portfolio and Receives a Favorable Patent Claim Opinion
Cybin announces the filing of a non-provisional patent application, the company's 14th patent application.
MindMed Joins Critical Path Institute's Patient-Reported Outcome Consortium
MindMed announces joining a research consortium, the Patient-Reported Outcome Consortium, to assist in its mission to advance medical innovation.
Psychedelic Toad Venom Clinical Research Boosted by $80M in Funding
Oxford-based startup Beckley Psytech in the United Kingdom announced August 15 that it raised $80 million to ramp up clinical trials and research using a pharmaceutical formulation of 5-MeO-DMT, a powerful compound produced endogenously by Sonoran Desert toad venom, to treat depression.
MindMed Announces 2021 Q2 Financial Results; Cash Balance of $157 USD Million ($195 CAD Million) to Execute on Diverse Clinical Pipeline
MindMed reports a Q2 2021 loss of $36 million. Current cash on hand of $157 million.
GOP Congressman Who Voted Against Psychedelics Amendment Says MDMA Therapy ‘Sounds Amazing’
A Republican congressman who’s voted against modest measures to loosen barriers on psychedelic research seems to be coming around on the issue following discussions with advocates—including military veterans who have utilized the substances therapeutically—and now says the treatment “sounds amazing.”
Is Access To Psychedelic Medicine The Largest Human Rights Issue Today?
The Mental Health Crisis is now a mental health pandemic. Is access to psychedelic medicine the world's largest human rights issue?